IGC Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -711.67% compared to IGC Pharma's net margin of --. IGC Pharma's return on equity of -116.24% beat CEL-SCI's return on equity of --.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1059.83%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 6699.55%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

IGC Pharma has a beta of 1.452, which suggesting that the stock is 45.212% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are larger than CEL-SCI quarterly revenues of --. IGC Pharma's net income of -$1.8M is higher than CEL-SCI's net income of -$6.6M. Notably, IGC Pharma's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 20.11x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Lineage Cell Therapeutics has a net margin of -711.67% compared to IGC Pharma's net margin of -275.57%. IGC Pharma's return on equity of -116.24% beat Lineage Cell Therapeutics's return on equity of -22.68%.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1059.83%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 283.99%. Given that IGC Pharma has higher upside potential than Lineage Cell Therapeutics, analysts believe IGC Pharma is more attractive than Lineage Cell Therapeutics.

IGC Pharma has a beta of 1.452, which suggesting that the stock is 45.212% more volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.603, suggesting its more volatile than the S&P 500 by 60.322%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are smaller than Lineage Cell Therapeutics quarterly revenues of $1.5M. IGC Pharma's net income of -$1.8M is higher than Lineage Cell Therapeutics's net income of -$4.1M. Notably, IGC Pharma's price-to-earnings ratio is -- while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 20.11x versus 22.52x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -711.67% compared to IGC Pharma's net margin of -49.65%. IGC Pharma's return on equity of -116.24% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1059.83%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that IGC Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe IGC Pharma is more attractive than NovaBay Pharmaceuticals.

IGC Pharma has a beta of 1.452, which suggesting that the stock is 45.212% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGC Pharma's net income of -$1.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, IGC Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 20.11x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -711.67% compared to IGC Pharma's net margin of -35.79%. IGC Pharma's return on equity of -116.24% beat Protalix BioTherapeutics's return on equity of 10.9%.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1059.83%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 879.02%. Given that IGC Pharma has higher upside potential than Protalix BioTherapeutics, analysts believe IGC Pharma is more attractive than Protalix BioTherapeutics.

IGC Pharma has a beta of 1.452, which suggesting that the stock is 45.212% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. IGC Pharma's net income of -$1.8M is higher than Protalix BioTherapeutics's net income of -$3.6M. Notably, IGC Pharma's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 20.11x versus 2.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.